Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$68.55 USD

68.55
1,378,444

+1.18 (1.75%)

Updated Sep 18, 2025 04:00 PM ET

After-Market: $68.55 0.00 (0.00%) 7:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 245)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Henry Schein (HSIC) Down 0.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Henry Schein (HSIC) Q2 Earnings Top Estimates, Margins Dip

by Zacks Equity Research

Henry Schein (HSIC) sees dismal segmental performance in Q2 due to disruptions resulting from the coronavirus pandemic.

Zacks Equity Research

Henry Schein (HSIC) Reports Break-Even Earnings for Q2

by Zacks Equity Research

Henry Schein (HSIC) delivered earnings and revenue surprises of 100.00% and 19.98%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Earnings Season Could Be Great for Henry Schein (HSIC)

by Zacks Equity Research

Henry Schein (HSIC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Henry Schein (HSIC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Henry Schein (HSIC) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) medical business' PPE sales are likely to have boosted Q2 performance amid the coronavirus pandemic.

Zacks Equity Research

Why the Earnings Surprise Streak Could Continue for Henry Schein (HSIC)

by Zacks Equity Research

Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Henry Schein Banks on Dental Consumable Amid Coronavirus Woes

by Zacks Equity Research

Henry Schein (HSIC) seems upbeat about its dental technology business, Henry Schein One.

Zacks Equity Research

Henry Schein Medical to Expand in Telemedicine With VisualDx

by Zacks Equity Research

Henry Schein's (HSIC) VisualDx system to be integrated with Medpod's technology infrastructure for improved patient outcome.

Trina Mukherjee headshot

3 MedTech Stocks to Buy Amid Intensifying Coronavirus Fears

by Trina Mukherjee

Let's keep a watch on three stocks that have shown tremendous promise amid the pandemic.

Trina Mukherjee headshot

Near-Term Outlook Bleak for Medical Dental Supplies Industry

by Trina Mukherjee

Digital influence coupled with AI & Robotics can drive the medical dental supplies industry amid the coronavirus-induced crisis.

Zacks Equity Research

Henry Schein Dental Software Arm May Rebound Despite Pandemic

by Zacks Equity Research

Henry Schein (HSIC) also seems to be upbeat about its dental technology business, Henry Schein One.

Zacks Equity Research

Why Is Henry Schein (HSIC) Up 20% Since Last Earnings Report?

by Zacks Equity Research

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Henry Schein Sales Drop on Coronavirus Woes, Costs Rise

by Zacks Equity Research

Henry Schein (HSIC) registers dismal performance within Dental business on suspension of non-emergency procedures in response to the pandemic.

Zacks Equity Research

Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Henry Schein (HSIC) sees dismal performance by Dental arm in Q1 due to disruptions resulting from the coronavirus pandemic.

Zacks Equity Research

Analysts Estimate Henry Schein (HSIC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Contribution from Henry Schein's (HSIC) medical business in the form of point-of-care antibody rapid test is likely to have boosted Q1 performance amid the coronavirus pandemic.

Sweta Jaiswal, FRM headshot

Healthcare ETFs to Gain on Progress in COVID-19 Antibody Tests

by Sweta Jaiswal, FRM

Along with molecular testing, antibody testing is gaining immense prominence as economies are struggling to reopen.

Sweta Jaiswal, FRM headshot

Healthcare Stocks & ETFs to Gain on Coronavirus Test Progress

by Sweta Jaiswal, FRM

It seems that testing for COVID-19 is the major key in controlling the outbreak and helps in making decisions like treatment protocols, resource allocation and drafting the right healthcare policies.

Zacks Equity Research

BD Launches New Test to Help Combat the Coronavirus Outbreak

by Zacks Equity Research

BD (BDX), along with BioMedomics, launches a new point-of-care test to help fight the coronavirus outbreak.

Sweta Jaiswal, FRM headshot

Healthcare ETFs Gain on Rising Demand for COVID-19 Tests

by Sweta Jaiswal, FRM

A growing demand for COVID-19 tests has indulged major healthcare place in the race to develop competent testing kits.

Zacks Equity Research

Henry Schein (HSIC) Jumps: Stock Rises 7.1%

by Zacks Equity Research

Henry Schein (HSIC) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Zacks Equity Research

Why Is Henry Schein (HSIC) Down 34.7% Since Last Earnings Report?

by Zacks Equity Research

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Trina Mukherjee headshot

4 Potential Gainers Amid Intensifying Coronavirus Fears

by Trina Mukherjee

Amid the pandemonium associated with coronavirus, we look into four stocks that have the potential to benefit from this outbreak.

Zacks Equity Research

Henry Schein (HSIC) Expands by Signing JV With Casa Schmidt

by Zacks Equity Research

Henry Schein (HSIC) strengthens position in Spain and Portugal by signing a JV with Casa Schmidt.